Attention-deficit hyperactivity disorder on the frontlines: Management in the primary care office

Comprehensive Therapy

Volumn 25, Issue 6-7, 1999, Pages 313-325

  Taylor, Michael A ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Box 870378 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DIETHYLCARBAMAZINE; GUANFACINE; IMIPRAMINE; LITHIUM; METHAMPHETAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PEMOLINE; PEMOLINE MAGNESIUM; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; PATIENT EDUCATION; PSYCHIATRIC DIAGNOSIS;

EID: 0032865612     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02944277     Document Type: Article

References (49)

1. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J. Am Acad Child Adoles Psychiatr. 1996;35:978-987.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
3. Baren M. ADHD: do we finally have it right? Contemp Pediatr. 1994;11:95-124.
4. Shrand JA, Jellinek MS. Psychopharmacology in office practice. Contemp Pediatr. 1995;12:106-118.
5. Castellanos FX. Toward a pathophysiology of attentiondeficit/hyperactivity disorder. Clin Pediatr. 1997;36:381-393.
6. Barkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, NY: The Guilford Press, 1990.
7. Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children: a meta-analysis. JAMA. 1995;274:1617-1621.
8. Baren M. Managing ADHD. Contemp Pediatr. 1994; 11:29-48.
9. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: an 8-year prospective follow-up study. J. Am Acad Child Adolesc Psychiatr. 1990;29:546-557.
10. Manuzza S, Klein RG, Bessler A, Malloy P, La Padula M. Adult outcome of hyperactive boys. Arch Gen Psychiatr. 1993;50:565-576.
11. Wilens TE, Biederman J, Spencer TJ, Frances RJ. Comorbidity of attention-deficit hyperactivity and psychoactive substance use disorders. Hosp Com Psych. 1994;45:421-435.
12. Phillips S, Soffer SL. Recent advances regarding attention deficit-hyperactivity disorder in adolescence. Curr Opin Pediatr. 1996;8:310-318.
13. Weiss G, Hechtman LT. Hyperactive Children Grown Up: ADHD in Children, Adolescents, and Adults. 2nd ed. New York, NY: The Guilford Press, 1993.
14. Baren M, Swanson JM. How not to diagnose ADHD. Contemp Pediatr. 1996;13:53-64.
15. Pliszka SR. Attention-deficit hyperactivity disorder: a clinical review. Am Fam Phys. 1991:43:1267-1275.
16. Goldstein S, Goldstein M. Managing Attention Disorders in Children: A Guide for Practitioners. New York, NY: John Wiley & Sons, 1990.
17. Goldstein S. Managing Attention and Learning Disorders in Late Adolescence & Adulthood: A Guide for Practitioners. New York, NY: John Wiley & Sons, Inc., 1997.
18. Sleator EK, Ullman RK. Can the physician diagnose hyperactivity in the office? Pediatrics. 1981;67:13-17.
19. Johnson TM. Evaluating the hyperactive child in your office: is it ADHD? Am Fam Phys. 1997;56:155-163.
20. Dupaul GI, Anastopoulos AD, Shelton TL, Guevremont DC, Metevia L. Multimethod assessment of attention-deficit hyperactivity disorder: the diagnostic utility of clinic-based tests. J Clin Child Psychol. 1992;21:194-402.
21. Wolraich ML, Baumgaertel A. The practical aspects of diagnosing and managing children with attention deficit hyperactivity disorder. Clin Pediatr. 1997;36:497-504.
22. Reiff MI. Adolescent school failure: failure to thrive in adolescence. Pediatr Rev. 1998;19:199-207.
23. Kamphaus RW, Frick PJ. Clinical Assessment of Child and Adolescent Personality and Behavior. Needham Heights, MA: Allyn and Bacon, 1996.
24. Blondis TA, Accardo PJ, Snow JH. Measures of attention deficit, part I: questionnaires. Clin Pediatr. 1989;28:222-228.
25. Barbaresi WJ. Primary-care approach to the diagnosis and management of attention-deficit hyperactivity disorder. Mayo Clin Proc. 1996;71:463-471.
26. Searight HR, Nahlik JE, Campbell DC. Attentiondeficit/hyperactivity disorder: assessment, diagnosis, and management. J Fam Prac. 1995;40:270-279.
27. Adesman AR, Wender EH. Improving the outcome for children with ADHD. Contemp Pediatr. 1991;March:122-139.
28. Brown FR, Voigt RG, Elksnin N. AD/HD: a neurodevelopmental perspective. Contemp Pediatr. 1996;13:25-44.
29. Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. J Dev Behav Pediatr. 1990;11:269-271.
30. American Academy of Pediatrics. Committee on Children with Disabilities and Committee on Drugs. Medication for children with attentional disorders. Pediatrics. 1996;98:301-304.
31. Gillberg C, Melander H, von Knorring A, Janols L, Thernlund G, Hagglor B, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. Arch Gen Psychiatr. 1997;54:857-864.
32. Culbert TP, Banez GA, Reiff MI. Children who have attentional disorders: interventions. Pediatr Rev. 1994;15:5-14.
33. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adoles Psychiatr. 1996;35:409-432.
34. Barkley RA, Murphy JV. Treating attention-deficit hyperactivity disorder: medication and behavior management training. Pediatr Ann. 1991;20:256-266.
35. Klein R, Mannuzza S. Hyperactive boys almost grown up: methylphenidate effects on ultimate height. Arch Gen Psychiatr. 1988;45:1131.
36. Feldman H, Crumrine P, Handen BL, Alvin R, Teodori J. Methyphenidate in children with seizures and attention-deficit disorder. Amer J Dis Child. 1989;143:1081-1086.
37. Novartis Pharmaceuticals Corp. Ritalin® package insert. In: Physician's Desk Reference. 52nd ed. Oradell, NJ: Medical Economics Data, 1998.
38. SmithKline Beecham Pharmaceuticals. Dexedrine® package insert. In: Physician's Desk Reference. 52nd ed. Oradell, NJ: Medical Economics Data, 1998.
39. Shire-Richwood Pharmaceutical Co. Inc. Dextrostat® package insert. In: Physician's Desk Reference. 52nd ed. Oradell, NJ: Medical Economics Data, 1998.
40. Swanson JM, Wigal S, Greenhill LL, Browne R, Waslik B, Lerner M, et al. Analog classroom assessment of Adderall® in children with ADHD. J Amer Acad Child Adoles Psychiatr. 1998;37:519-525.
41. Rosenberg DR, Holttum J, Ryan N, Gershon S. Pocket Guide for the Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disorders. Washington, DC: Taylor & Francis, 1998.
42. Abbott Laboratories, Desoxyn® package insert. In: Physician's Desk Reference. 52nd ed. Oradell, NJ: Medical Economics Data, 1998.
43. Wender PH. Methamphetamine in child psychiatry. J Child Adolesc Psychopharm. 1993;3:4-6.
44. Perez-Reyes M, White WR, McDonald SA, et al. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 1991;14:352-358.
45. Abbott Laboratories. Cylert® package insert. In: Physician's Desk Reference. 52nd ed. Oradell, NJ: Medical Economics Data, 1998.
46. Marotta PJ, Roberts EA. Pemoline hepatoxicity in children. J Pediatr. 1998;132:894-897.
47. Nehra A, Mullick F, Ishak KG, Zimmerman HJ. Pemolineassociated hepatic injury. Gastroenterology. 1990;99:1517-1519.
48. Rosh JR, Dellert SF, Narkewicz M, Birnbaum A, Whitington G. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. Pediatrics. 1998:101;921-923.
49. Greenburg DM. Summertime: the right time for ADHD medications. Contemp Pediatr. 1997;14:154-155.